Nyxoah Posts Strong Q2 2026 Growth on U.S. Momentum and Reimbursement Boost
Event summary
- Nyxoah reported €7.7M in global net revenue for Q2 2026, up 21% sequentially.
- U.S. revenue grew 22% sequentially to €5.2M, driven by 89 new accounts and 55 new surgeons trained.
- CMS proposed a 12-15% reimbursement increase for the Genio procedure in hospitals and ASCs.
- $110M in financing secured in Q2, bringing total liquidity to €97.8M.
The big picture
Nyxoah's Q2 results highlight the accelerating adoption of its Genio system in the U.S., where reimbursement dynamics and commercial scaling are critical. The proposed CMS rate increases, if approved, would further solidify the economic viability of Nyxoah's offering against competitors in the neuromodulation space for obstructive sleep apnea.
What we're watching
- Commercial Execution
- Whether Nyxoah can sustain its rapid U.S. expansion and surgeon training pace.
- Regulatory Approval
- The likelihood of CMS finalizing the proposed reimbursement increases for 2027.
- Path to Profitability
- How quickly Nyxoah can translate revenue growth into profitability with its current cash runway.
Related topics